
life science investment banking
Acquirer | Target | Amount |
Enzon Pharmaceuticals | Abelcet product from Elan | $360,000,000 |
Smith & Nephew plc | Acufex unit of American Home Products | $141,000,000 |
Smith & Nephew plc | Advanced Tissue Sciences (Joint Venture Formation) | $70,000,000 |
Nektar | Aerogen | $32,000,000 |
MDL | Afferent Systems | Undisclosed |
Astellas | Agensys | $537,000,000 |
Ligand | ALRT formed with Allergan | Undisclosed |
Marquette Electronics | American Home Products (Divestiture of Corometrics) | $74,000,000 |
Gensia | Aramed | $38,000,000 |
Bio Participations | Becton, Dickinson and Company (Sale of Equity Stake of BMH S.A.) | Undisclosed |
Marmon Group | BG Sulzle | Undisclosed |
Genzyme | Biosurface Technology | Undisclosed |
Medchem | C.R. Bard | $102,000,000 |
ArQule | Camitro | $85,000,000 |
Cephalon | Cephalon Clinical Partners | Undisclosed |
Ciba-Geigy Ltd. | Chiron Corporation | $2,000,000,000 |
Purdue Frederick | CoCensys | $9,500,000 |
Chiroscience | Darwin Molecular | $120,000,000 |
Johnson & Johnson | DePuy | $3,700,000,000 |
Invitrogen | Dexter and Life Technologies | $1,900,000,000 |
Alkermes | Enzytech | $33,000,000 |
Protein Design Labs | ESP Pharma | $500,000,000 |
Structural Bioinformatics | GeneFormatics | Undisclosed |
Bio-Technology General | Gynex | $52,185,000 |
Eli Lilly | Isis Pharmaceuticals | $200,000,000 |
Pacific Dunlop Ltd. | Johnson & Johnson Glove Business | $98,000,000 |
Arris | Khepri | $22,000,000 |
Pfizer | Medivation | $725,000,000+ |
Novartis | Nektar | $115,000,000 |
PerkinElmer, Inc. | NEN Life Sciences | $405,000,000 |
Autocyte Inc. | NeoPath | $96,000,000 |
Genzyme | Neozyme II | $109,000,000 |
Cell Therapeutics | Novuspharma S.p.A. | $238,000,000 |
Arca Biopharma | Nuvelo | Undisclosed |
St. Jude Medical, Inc. | Pacesetter Business of Siemens AG | $500,000,000 |
Amersham International plc | Pharmacia Biotech (Joint Venture Formation) | Undisclosed |
Incyte | Proteome | $77,000,000 |
Corixa | Ribi Immunochem | $58,500,000 |
Investor Group | Roche (Sale of Cedia Diagnostics Business) | Undisclosed |
Cephalon | Salmedix | $160,000,000 |
Pacific Dunlop (Ansell Int'l Unit) | Smith & Nephew plc (Perry Glove Division) | $55,000,000 |
Sulzer Medica | Spine-Tech | $595,000,000 |
Incyte | Synteni | $114,000,000 |
St. Jude Medical, Inc. | Telectronics, Inc. | $135,000,000 |
Centocor | Tocor II | $90,000,000 |
Myriad Genetics (spin-off of pharma business) | Undisclosed | Undisclosed |
St. Jude Medical, Inc. | Ventritex, Inc. | $363,000,000 |
UCB S.A. (Belgium) | Whitby Pharmaceutical Subsidiary of Ethyl Corp. (Divestiture of Subsidiary) | $63,000,000 |
Agensys | $42,800,000 | AGY Therapeutics | $31,300,000 | Alkermes | $46,000,000 | ||||||
Amylin Pharmaceuticals | $100,000,000 | Ariad Pharmaceuticals | $46,000,000 | AtheroGenics, Inc. | $20,600,000 | ||||||
Caliper Technologies | $110,400,000 | Censtor | $20,900,000 | Centene | $18,000,000 | ||||||
Cephalon | $125,000,000 | Cephalon | $45,000,000 | Corgentech | $50,400,000 | ||||||
DAOU Systems | $12,000,000 | Darwin | $30,000,000 | Durect | $20,000,000 | ||||||
DUSA Pharmaceuticals | $42,750,000 | Gene Logic | $20,000,000 | Genentech | $72,500,000 | ||||||
Genesoft | $21,800,000 | Gensia | $26,300,000 | Gensia | $80,000,000 | ||||||
Genzyme | $36,800,000 | Halozyme Therapeutics | $17,000,000 | Halozyme Therapeutics | $14,000,000 | ||||||
HealthCentral | $22,000,000 | IGEN | $25,000,000 | Insite Vision | $8,800,000 | ||||||
Intermune | $27,300,000 | Invitrogen | $172,500,000 | Khepri Pharmaceuticals | $11,000,000 | ||||||
LogistiCare | $20,000,000 | Martek Biosciences | $20,300,000 | Martek Biosciences | $10,000,000 | ||||||
Maxim | $20,600,000 | Myogen, Inc. | $66,400,000 | Neocrin | $16,000,000 | ||||||
NetGenics | $17,700,000 | Paradigm Genetics | $28,000,000 | Protein Design Labs, Inc. | $150,000,000 | ||||||
ReGen Biologics | $8,600,000 | Repligen | $45,000,000 | Ribi ImmunoChem | $12,000,000 | ||||||
Saegis Pharmaceuticals | $30,000,000 | Sciquest.com | $37,500,000 | Selfcare | $41,500,000 | ||||||
Signal Pharmaceuticals | $12,000,000 | Skila Inc. | $26,100,000 | Solexa | $65,000,000 | ||||||
Solexa | $32,000,000 | Sunesis Pharmaceuticals | $45,000,000 | Synergen | $52,500,000 | ||||||
Targeted Genetics, Inc. | $17,500,000 | Targeted Genetics, Inc. | $30,300,000 | The Liposome Company, Inc. | $15,000,000 | ||||||
Therion | $10,500,000 | Transgenomic | $12,000,000 | Transkaryotic Therapies | $15,600,000 | ||||||
Valentis, Inc. | $19,200,000 | Xenon Genetics | $44,900,000 |
Array BioPharma | $91,000,000 | Follow-On | Atherogenics | $48,000,000 | Initial Public Offering | |||
AutoImmune | $56,000,000 | Follow-On | Axys | $17,500,000 | Initial Public Offering | |||
Axys | $44,900,000 | Follow-On | Caliper Technologies | $83,000,000 | Initial Public Offering | |||
Centocor | $64,700,000 | Follow-On | Centocor | $132,800,000 | Follow-On | |||
Cephalon | $89,700,000 | Follow-On | CoCensys | $15,800,000 | Follow-On | |||
Connetics | $22,800,000 | Follow-On | Discovery Partners | $103,500,000 | Initial Public Offering | |||
Dura | $160,300,000 | Follow-On | Dura | $158,700,000 | Follow-On | |||
Durect | $96,600,000 | Initial Public Offering | Endovascular Tech. | $24,000,000 | Initial Public Offering | |||
Exelixis Pharmaceuticals | $118,000,000 | Initial Public Offering | Genencor International | $145,000,000 | Initial Public Offering | |||
Genomic Health | $47,000,000 | Follow-On | Gensia | $68,000,000 | Follow-On | |||
Gensia/Aramed | $50,000,000 | Initial Public Offering | Gilead | $82,000,000 | Follow-On | |||
I-Stat | $35,200,000 | Follow-On | IGEN | $30,000,000 | Initial Public Offering | |||
ImmuLogic | $25,800,000 | Follow-On | Incyte | $34,900,000 | Follow-On | |||
Incyte | $92,300,000 | Follow-On | Intermune | $125,000,000 | Initial Public Offering | |||
Invitrogen | $147,500,000 | Follow-On | King | $91,900,000 | Initial Public Offering | |||
Lexicon Genetics | $220,000,000 | Initial Public Offering | Ligand | $38,000,000 | Follow-On | |||
MannKind Corporation | $515,000,000 | Follow-On/Convertible Offering | Medicis | $197,000,000 | Follow-On | |||
Myriad Genetics | $197,000,000 | Follow-On | NeoPath | $60,000,000 | Follow-On | |||
Novoste | $55,200,000 | Follow-On | Orexigen Therapeutics | $97,000,000 | Initial Public Offering | |||
OrthoLogic | $78,400,000 | Follow-On | Protein Design Labs, Inc. | $362,000,000 | Follow-On | |||
SangStat | $42,000,000 | Follow-On | SangStat | $78,000,000 | Follow-On | |||
Seattle Genetics | $100,000,000 | Follow-On | Shire | $100,000,000 | Follow-On | |||
Sonus | $20,000,000 | Initial Public Offering | SpectRx | $15,400,000 | Initial Public Offering | |||
Sugen | $24,800,000 | Follow-On | Sulzer Medica | $620,000,000 | Initial Public Offering | |||
Sunesis Pharmaceuticals | $42,000,000 | Initial Public Offering | Telik | $35,000,000 | Initial Public Offering | |||
Uromed | $40,000,000 | Initial Public Offering | Variagenics | $88,000,000 | Initial Public Offering | |||
Versicor | $50,600,000 | Initial Public Offering |